GlycoNAVI-Proteins is dataset of glycan and protein information. This is the content of GlycoNAVI.
Source | Last Updated |
---|---|
GlycoNAVI Proteins | November 28, 2024 |
PDB ID | UniProt ID | Title ▼ | Descriptor |
---|---|---|---|
7YCK | 7YCK | Crystal structure of SARS-CoV-2 Spike RBD in complex with FP-12A Fab | |
7LY3 | P0DTC2 | Crystal structure of SARS-CoV-2 S NTD bound to S2M28 Fab | |
7LY3 | 7LY3 | Crystal structure of SARS-CoV-2 S NTD bound to S2M28 Fab | |
7WUE | P0DTC2 | Crystal structure of SARS-CoV-2 Receptor Binding Domain in complex with the monoclonal antibody m31A7 | |
7WUE | 7WUE | Crystal structure of SARS-CoV-2 Receptor Binding Domain in complex with the monoclonal antibody m31A7 | |
7YCO | P0DTC2 | Crystal structure of SARS-CoV-2 Receptor Binding Domain bound to A6 repebody | |
7YCO | 7YCO | Crystal structure of SARS-CoV-2 Receptor Binding Domain bound to A6 repebody | |
8GX9 | P0DTC2 | Crystal structure of SARS-CoV-2 RBD with P2C-1F11 and P2B-1G5 | |
8GX9 | 8GX9 | Crystal structure of SARS-CoV-2 RBD with P2C-1F11 and P2B-1G5 | |
7UL0 | P0DTC2 | Crystal structure of SARS-CoV-2 RBD in complex with the ridge-binding nAb EH8 isolated from a nonvaccinated pediatric patient | |
7UL0 | 7UL0 | Crystal structure of SARS-CoV-2 RBD in complex with the ridge-binding nAb EH8 isolated from a nonvaccinated pediatric patient | |
7Q3Q | A0A6H2EIN2 | Crystal structure of SARS-CoV-2 RBD in complex with the neutralizing nanobody VHH-12 | |
7Q3Q | 7Q3Q | Crystal structure of SARS-CoV-2 RBD in complex with the neutralizing nanobody VHH-12 | |
7Q3R | A0A6H2EIN2 | Crystal structure of SARS-CoV-2 RBD in complex with the neutralizing nanobodies VHH-F04 and VHH-G09 | |
7Q3R | 7Q3R | Crystal structure of SARS-CoV-2 RBD in complex with the neutralizing nanobodies VHH-F04 and VHH-G09 | |
7UL1 | P0DTC2 | Crystal structure of SARS-CoV-2 RBD in complex with the neutralizing IGHV3-53-encoded antibody EH3 isolated from a nonvaccinated pediatric patient | |
7UL1 | 7UL1 | Crystal structure of SARS-CoV-2 RBD in complex with the neutralizing IGHV3-53-encoded antibody EH3 isolated from a nonvaccinated pediatric patient | |
7E5O | P0DTC2 | Crystal structure of SARS-CoV-2 RBD in complex with antibody NT-193 | |
7E5O | 7E5O | Crystal structure of SARS-CoV-2 RBD in complex with antibody NT-193 | |
7VOA | 7VOA | Crystal structure of SARS-CoV-2 RBD in complex with aRBD5 | |
7VOA | P0DTC2 | Crystal structure of SARS-CoV-2 RBD in complex with aRBD5 | |
7DET | P0DTC2 | Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv | |
7DET | 7DET | Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv | |
7DEU | P0DTC2 | Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv | |
7DEU | 7DEU | Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv | |
7DEO | 7DEO | Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv | |
7DEO | P0DTC2 | Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv | |
7CJF | 7CJF | Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody Fab | |
7CJF | P0DTC2 | Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody Fab | |
7KM5 | P0DTC2 | Crystal structure of SARS-CoV-2 RBD complexed with Nanosota-1 | |
7KM5 | 7KM5 | Crystal structure of SARS-CoV-2 RBD complexed with Nanosota-1 | |
7DHX | 7DHX | Crystal structure of SARS-CoV-2 RBD binding to pangolin ACE2 | |
7DHX | P0DTC2 | Crystal structure of SARS-CoV-2 RBD binding to pangolin ACE2 | |
7E3J | 7E3J | Crystal structure of SARS-CoV-2 RBD binding to dog ACE2 | |
7E3J | P0DTC2 | Crystal structure of SARS-CoV-2 RBD binding to dog ACE2 | |
7FC5 | F6V9L3 | Crystal structure of SARS-CoV-2 RBD and horse ACE2 | |
7FC5 | P0DTC2 | Crystal structure of SARS-CoV-2 RBD and horse ACE2 | |
8HES | P0DTC2 | Crystal structure of SARS-CoV-2 RBD and NIV-10 complex | |
8HES | 8HES | Crystal structure of SARS-CoV-2 RBD and NIV-10 complex | |
7P19 | Q9BYF1 | Crystal structure of SARS-CoV-2 RBD Q498Y complexed with human ACE2 | |
7P19 | P0DTC2 | Crystal structure of SARS-CoV-2 RBD Q498Y complexed with human ACE2 | |
7WSK | Q56NL1 | Crystal structure of SARS-CoV-2 Omicron spike receptor-binding domain in complex with civet ACE2 | |
7WSK | P0DTC2 | Crystal structure of SARS-CoV-2 Omicron spike receptor-binding domain in complex with civet ACE2 | |
7FJC | P0DTC2 | Crystal structure of SARS-CoV-2 Beta RBD complexed with P36-5D2 Fab | |
7FJC | 7FJC | Crystal structure of SARS-CoV-2 Beta RBD complexed with P36-5D2 Fab | |
8GB8 | P0DTC2 | Crystal structure of SARS-CoV-2 BA.2 receptor binding domain in complex with neutralizing antibody 20A7 | |
8GB8 | 8GB8 | Crystal structure of SARS-CoV-2 BA.2 receptor binding domain in complex with neutralizing antibody 20A7 | |
7S5P | P0DTC2 | Crystal structure of SARS-CoV-2 B.1.351 variant receptor binding domain in complex with neutralizing antibody CS23 | |
7S5P | 7S5P | Crystal structure of SARS-CoV-2 B.1.351 variant receptor binding domain in complex with neutralizing antibody CS23 | |
7S5Q | P0DTC2 | Crystal structure of SARS-CoV-2 B.1.351 variant receptor binding domain in complex with neutralizing antibodies CS44 and COVA1-16 |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
GlyCosmos Portal v4.0.0
Last updated: August 19, 2024